OncoMatch/Clinical Trials/NCT06696833
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
Is NCT06696833 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including QH10304-BAL-01 and Fludarabine for b-cell acute lymphoblastic leukemia, adult.
Treatment: QH10304-BAL-01 · Fludarabine · Cyclophosphamide — This clinical trial aims to investigate the safety, optimal dosage, and effectiveness of allogeneic CD19-targeted CAR-γδT Cell in treating CD19-positive relapsed/refractory B-ALL
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 positive expression (positive)
Disease stage
Required: Stage RELAPSED, REFRACTORY
Excluded: Stage ISOLATED EXTRAMEDULLARY RELAPSE
Meet the diagnosis of relapsed/refractory leukemia, excluding isolated extramedullary relapse
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CAR-T cell therapy
Exception: within 6 months before screening
Patients who have previously received CAR-T cell therapy within 6 months
Cannot have received: donor lymphocyte infusion
Exception: within 6 weeks before screening
donor lymphocyte infusion within 6 weeks before screening
Lab requirements
Kidney function
Creatinine ≤1.5×ULN
Liver function
Total bilirubin (TBil) ≤3×ULN, AST and ALT ≤3×ULN
Cardiac function
Left ventricular ejection fraction (LVEF) ≥50%
The vital organs function in accordance with the following requirements: 7.1Left ventricular ejection fraction (LVEF) ≥50%; 7.2Pulmonary function：normal oxygen saturation without oxygen supplementation; 7.3Total bilirubin (TBil) ≤3×ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3×ULN； 7.4Creatinine ≤1.5×ULN;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify